Catalent Geno Therapy has Signed an Agreement with AstraZeneca to manufacture a COVID-19 Vaccine at their Greater Baltimore Facility Near BWI
Catalent Geno Therapy has signed an agreement with AstraZeneca to manufacture a COVID-19 vaccine at their Greater Baltimore facility near BWI. According toTechnical.ly Baltimore, the 200,000 sf facility was acquired last year by New Jersey-based Catalent when it bought Baltimore-born Paragon Bioservices in a $1.2B deal. “The company is pleased to have the capabilities at our flagship Catalent Gene Therapy site to expand our support for the AstraZeneca program, while continuing to serve our current gene therapy customers,” said President Dr. Manja Boerman.